CC-90010, A Reversible, Oral Bromodomain And Extra-terminal (BET ...
ESMOMeeting CalendarOncologyPRODaily ReporterLoginNo results foundSearchLegal
- Terms of Use
- Privacy Policy
- Change cookie settings
Useful links
- About OncologyPRO
- Sponsors
- Contact us
Subscribe to ESMO newsletter
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH © Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.Từ khóa » Cc-90010
-
Phase I Study Of CC-90010, A Reversible, Oral BET Inhibitor In ...
-
Phase I Study Of CC-90010, A Reversible, Oral BET Inhibitor In ...
-
A Study To Assess The Safety, Tolerability, Pharmacokinetics And ...
-
Trotabresib (CC-90010) | BET Inhibitor - MedChemExpress
-
BET Inhibitor CC-90010 Shows Activity In Advanced Solid Tumors ...
-
Phase I Study Of CC-90010 In Patients With ... - ASCO Journals
-
CC-90010 | Selleck | Epigenetic Reader Domain Inhibitor
-
Under Fasting And Fed Conditions, CC-90010 Efficacy Remains ...
-
CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A ...
-
CC-90010 Is A Reversible And Orally Active BET Inhibitor
-
Phase I Study Of CC-90010 In Patients With ... - ResearchGate
-
Phase I Study Of CC-90010, A Reversible, Oral BET ... - Europe PMC
-
Cc 90010 Clinical Trials 2022 - Clincosm
-
Phase I Study Of CC-90010 In Patients With Advanced Solid Tumours ...